Skip to content
NovAccess Global Logo
XSNX 0.18 0.00 0.00%
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact
Menu
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact
NovAccess Global Logo
XSNX 0.18 0.00 0.00%
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact
Menu
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact

Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award

March 15, 2023
Read More »

NovAccess Global to Present at World Orphan Drug Congress

February 16, 2023
Read More »

NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress

February 3, 2023
Read More »

NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company’s Lead Scientist and President of its StemVax Therapeutics Division

January 5, 2023
Read More »

NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate

November 22, 2022
Read More »
XSNX Shareholder Meeting

NovAccess Global Announces Virtual Annual Shareholders’ Meeting

November 8, 2022
Read More »
Orphan Drug Application Filing

NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1

October 26, 2022
Read More »

NovAccess Global Announces Fireside Chat with Board Member Perspectives

October 20, 2022
Read More »
XSNX Fireside Chat

NovAccess Global Announces Fireside Chat Series for the Investment Community

September 30, 2022
Read More »

NovAccess Global Announces Effectiveness of Form S1 Registration Statement

September 22, 2022
Read More »

NovAccess Global Announces Uplisting to OTCQB

August 10, 2022
Read More »
Orphan Drug Application Filing

NovAccess Global Announces Filing of Orphan Drug Application for TLR-AD1

July 19, 2022
Read More »

 NovAccess Global CEO Dwain Irvin Featured on MoneyTV 

June 14, 2022
Read More »

NovAccess Global to Participate in LD Micro Invitational XII Conference

May 19, 2022
Read More »

NovAccess Global Closes its Redemption Transaction and expands the Executive Board

March 17, 2022
Read More »

Revolutionary advances in the  understanding of how our bodies can fight cancer, and how to put that information to use in treating existing tumors. NovAccess Global’s team of experts is working to strengthen the capability of the human body’s defense against cancer.

Youtube Facebook Twitter Linkedin

Privacy Policy

Forward-Looking Statements

Contact Us

  • info@novaccessglobal.com
  • Corporate HQ
  • 8584 E. Washington Street #127 Chagrin Falls, Ohio 44023
  • Research & Development
  • 2265 E. Foothill Blvd, Pasadena, CA 91107

JOIN US

Stay up-to-date with our journey

Facebook Twitter Linkedin

Privacy Policy

Privacy Policy

Forward-Looking Statements